|
C17ORF42 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
8.61499982462988E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
6.259600E-01 |
| Stage1-vs-Stage3 |
1.553980E-02 |
| Stage1-vs-Stage4 |
8.8489000005243E-07 |
| Stage2-vs-Stage3 |
3.790200E-02 |
| Stage2-vs-Stage4 |
3.222200E-04 |
| Stage3-vs-Stage4 |
3.175900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.59620000445204E-08 |
| Normal-vs-Asian |
8.68659999486709E-09 |
| Caucasian-vs-AfricanAmerican |
5.017400E-01 |
| Caucasian-vs-Asian |
3.314000E-02 |
| AfricanAmerican-vs-Asian |
4.551400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.758600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
1.76290999999162E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.877700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.008210E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.208000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.228600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.636000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.372800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.461470E-03 |
| Classical-VS-Follicular |
2.458800E-01 |
| Classical-VS-Other |
7.363200E-01 |
| Classical-VS-Normal |
2.3125945602942E-13 |
| Tall-VS-Follicular |
7.413900E-04 |
| Tall-VS-Other |
2.528400E-01 |
| Tall-VS-Normal |
5.55111512312578E-16 |
| Follicular-VS-Other |
5.325200E-01 |
| Follicular-VS-Normal |
2.73659983562879E-11 |
| Other-VS-Normal |
3.765600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.18713935851156E-13 |
| N0-vs-N1 |
2.012800E-01 |
|
|
